An HCPLive feature reframes a central question in plaque psoriasis management: what counts as treatment success, and how should durable remission be defined?

The article, "Redefining Treatment Success and Remission in Psoriasis Care," consolidates how endpoint language has shifted across pivotal trials, treat-to-target frameworks, and everyday clinical practice.

Why does the PASI 75 benchmark no longer suffice?

For two decades, a 75% reduction in Psoriasis Area and Severity Index score anchored responder definitions in registration trials for moderate-to-severe plaque psoriasis. That threshold — PASI 75 — determined regulatory approval and reimbursement for the first wave of tumor necrosis factor inhibitors and remains in many current product labels.

Newer interleukin-17 and interleukin-23 inhibitors routinely deliver PASI 90 and PASI 100 responses in phase 3 readouts. That accumulated efficacy data has prompted treat-to-target frameworks in dermatology to call for absolute PASI ≤2 or complete clearance as the clinical goal, rather than relative improvement from baseline alone.

What does "remission" actually mean?

The HCPLive piece flags an unresolved definitional question: remission lacks a single agreed operational definition in plaque psoriasis. Candidate definitions circulating in recent consensus discussions include:

• Complete clearance (PASI 100) maintained over a defined interval
• Minimal residual disease on continuous biologic therapy, often operationalized as absolute PASI ≤2
• Drug-free remission sustained off systemic therapy for six months or longer

Each carries different implications for treatment holidays, step-down protocols, and payer conversations about continued coverage of maintenance biologics.

How are patient-reported outcomes reshaping the conversation?

PASI captures plaque extent, erythema, induration, and desquamation but does not directly measure itch, pain, sleep disruption, or functional impact. Instruments such as the Dermatology Life Quality Index and newer psoriasis-specific patient-reported outcome measures now appear as key secondary endpoints in pivotal trials and increasingly shape regulatory and payer assessments.

The shift aligns with broader FDA patient-focused drug development guidance that elevates patient experience data in approval decisions.

What three pressures drive the redefinition?

The article organizes the shift around three forces:

• Therapeutic potency that has rendered the original PASI 75 threshold obsolete
• Patient-reported instruments that surface what PASI alone misses
• Durability requirements measured across 12 to 24 months rather than at week 16

What questions remain unresolved?

The piece surfaces several decisions that will shape the next decade of psoriasis management:

• Should payers continue reimbursing biologic therapy for patients in durable remission?
• Can serum or tissue biomarkers replace clinician-rated severity scores in defining minimal disease activity?
• What duration of off-therapy clearance constitutes true remission?

Answers to those questions will determine label updates, payer coverage policies, and the structure of shared decision-making conversations between dermatologists and their patients.